Nathalie Laarakker
Director/Board Member at OXURION NV
Profile
Nathalie Laarakker is currently the Chief Financial Officer & Director at Intravacc BV since 2021.
She is also an Independent Non-Executive Director at Oxurion NV since 2023.
Previously, she held the position of Chief Financial Officer & Managing Director at Gadeta BV and Head-Finance at Merus NV.
Ms. Laarakker completed her undergraduate degree at the University of Amsterdam.
Nathalie Laarakker active positions
Companies | Position | Start |
---|---|---|
OXURION NV | Director/Board Member | 2023-05-01 |
Intravacc BV
Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Director of Finance/CFO | 2021-03-31 |
Former positions of Nathalie Laarakker
Companies | Position | End |
---|---|---|
MERUS N.V. | Corporate Officer/Principal | - |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | - |
Training of Nathalie Laarakker
University of Amsterdam | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
OXURION NV | Health Technology |
MERUS N.V. | Health Technology |
Private companies | 2 |
---|---|
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
Intravacc BV
Intravacc BV BiotechnologyHealth Technology Institute for Translational Vaccinology is a Dutch independent company that partners with clients in vaccine development, from discovery to pilot production to clinical studies. The non-profit company is based in Bilthoven, Netherlands. Intravacc designs and creates the best candidate organisms for vaccine strain, looking for the highest immunity, potency, and production yield. The company substantially reduces the risks and costs involved with developing vaccines by bridging the gap between concept and late-stage clinical studies. Intravacc's upstream processing expertise covers both bacterial and cell cultivation as well as virus propagation in reactors ranging from 1l up to 200l. The company's scientists design, develop, and improve vaccine formulations that are suitable for the intended administration route and stable upon storage. | Health Technology |
- Stock Market
- Insiders
- Nathalie Laarakker